| Literature DB >> 29322099 |
Nikos Ulrich1, Ralf-Peter Vonberg2, Petra Gastmeier1.
Abstract
BACKGROUND: Vancomycin-resistance in Enterococcus faecium (VRE) poses a major threat in health care settings. It is well known that patients in hematology and oncology departments are especially at risk of nosocomial VRE acquisition. This systematic review of the literature provides data on the main sources, transmission modes and potential risk factors for VRE acquisition as well as appropriate infection control measures in order to terminate such nosocomial outbreaks.Entities:
Keywords: Infectious disease; Internal medicine; Medicine; Oncology
Year: 2017 PMID: 29322099 PMCID: PMC5753762 DOI: 10.1016/j.heliyon.2017.e00473
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1PRISMA flow chart of literature search algorithm.
Fig. 2Distribution of outbreaks according to duration.
Isolation sites of VRE.
| Isolation site | Number (%) |
|---|---|
| stool, rectal swabs and perianal swabs | 267 (57%) |
| blood cultures | 141 (30%) |
| urine cultures | 27 (6%) |
| lung and chest | 20 (4%) |
| wound swabs | 6 (1%) |
| sputum samples | 5 (1%) |
| swabs from abdominal infections | 1 (0.2%) |
| swabs from skin infections | 1 (0.2%) |
Univariate and multivariate risk factors for acquisition of Vancomycin-resistant Enterococcus faecium in nosocomial outbreaks.
| Article | risk factors in univariate analysis | risk factors in multivariate analysis |
|---|---|---|
| * enteral feeding tube, gastrostomy tube or nasogastric tube | ||
| * lack of empirical contact precautions | ||
| * urinary catheter | ||
| * prior exposure to third-generation cephalosporins | ||
| * prior exposure to substances with anti-anaerobe activity | ||
| * acute myeloid leukemia | ||
| * vancomycin therapy during the previous 30 days | ||
| * antibiotic use within 1 month before admission | ||
| * low albumin levels at baseline | ||
| * cephalosporin use | ||
| * use of invasive devices | * young age | |
| * malignancy or sickle cell disease | * antimicrobial therapy | |
| * immunosuppression | ||
| * length of hospital stay | ||
| * male gender | ||
| * care in a 6-bed room | ||
| * more surgical, vancomycin or ceftizoxime therapy | ||
| * less metronidazole therapy | ||
| * gastrointestinal colonization with VRE | ||
| * exposure to metronidazole, clindamycin or imipenem | ||
| * administration of antibiotics | ||
| * administration of vancomycin | ||
| * length of hospital stay |
Fig. 3Distribution of infection control measures.